A common medication used to manage and treat HIV is becoming increasingly resistant, according to a report from the World Health Organization. Dolutegravir is an antiretroviral medication that is ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

GSK's antiretroviral HIV medicine Tivicay (dolutegravir) has been recommended by the World Health Organization (WHO) since 2018 as a preferred treatment for the virus. Now, the same agency is flagging ...

HIV virus is one of the most pressing health concerns facing the modern world. Since the first reported case of HIV/AIDS in 1981, over 25 million people have died. Out of the millions of people ...

Just as life is ever-evolving, so is the HIV treatment landscape. Thanks to decades of therapeutic improvements, people with HIV are living longer, healthier lives, but additional treatment needs may ...

LOS ANGELES — Lenacapavir, the twice-yearly injectable HIV drug, could potentially transform HIV prevention if it is approved as PrEP, research has shown. In the meantime, the drug is already approved ...

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

Two studies presented at this year's resistance meeting examined the clinical utility of resistance testing in prospective, randomized trials. Results of these studies are equivocal and raise ...

Effect of the Initial Regimen on the Rate of Specific Mutations Even among different HAART regimens, the selection of the initial regimen also has important implications in terms of selecting for ...

The announcement of the cuts prompted warnings from around the world about the potential consequences. In the Journal of ...